Published in J Drugs Dermatol on November 01, 2013
Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol (2006) 1.43
The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol (2011) 1.40
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Dermatofibrosarcoma protuberans: a case report and review of the literature. J Clin Aesthet Dermatol (2008) 1.16
Atypical mycobacterial cutaneous infections. Dermatol Clin (2009) 1.15
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol (2013) 1.08
Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol (2011) 1.07
Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis (2007) 1.03
Psoriasis and its comorbidities. J Drugs Dermatol (2012) 1.02
Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol (2009) 0.98
Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthet Dermatol (2013) 0.98
Anti-inflammatory activity of tetracyclines. Dermatol Clin (2007) 0.98
Calciphylaxis: a review. J Clin Aesthet Dermatol (2008) 0.98
Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol (2009) 0.92
Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol (2010) 0.92
Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol (2009) 0.92
Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol (2012) 0.92
Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin (2009) 0.91
Acne Vulgaris and the Epidermal Barrier: Is Acne Vulgaris Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity of the Epidermal Barrier? J Clin Aesthet Dermatol (2013) 0.90
A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol (2009) 0.89
Psychosocial judgements and perceptions of adolescents with acne vulgaris: A blinded, controlled comparison of adult and peer evaluations. Biopsychosoc Med (2011) 0.87
Skin cancer in asians: part 2: melanoma. J Clin Aesthet Dermatol (2009) 0.87
Pathogenesis of acne vulgaris: what's new, what's interesting and what may be clinically relevant. J Drugs Dermatol (2011) 0.86
Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol (2008) 0.85
The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis (2007) 0.85
Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis (2009) 0.85
Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol (2011) 0.85
Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol (2008) 0.84
Solitary sclerotic fibroma. J Clin Aesthet Dermatol (2009) 0.84
Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol (2013) 0.84
Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol (2008) 0.83
Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol (2008) 0.83
Advances in the Understanding of the Pathogenesis of Inflammatory Acne. J Drugs Dermatol (2016) 0.83
Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol (2009) 0.81
Combining clindamycin 1%-benzoyl peroxide 5% gel with multiple therapeutic options. Cutis (2006) 0.80
Tretinoin photostability: comparison of micronized tretinoin (0.05%) gel and tretinoin (0.025%) gel following exposure to ultraviolet a light. J Clin Aesthet Dermatol (2012) 0.80
What is new in fungal pharmacotherapeutics? J Drugs Dermatol (2014) 0.80
Absence of Degradation of Tretinoin When Benzoyl Peroxide is Combined with an Optimized Formulation of Tretinoin Gel (0.05%). J Clin Aesthet Dermatol (2010) 0.80
Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. J Drugs Dermatol (2013) 0.80
Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol (2013) 0.79
Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. J Clin Aesthet Dermatol (2009) 0.79
A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. Cutis (2009) 0.79
Use of a topical emulsion for wound healing. J Support Oncol (2008) 0.79
Tinea capitis in infants: recognition, evaluation, and management suggestions. J Clin Aesthet Dermatol (2012) 0.79
Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol (2011) 0.79
Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin (2007) 0.78
Evolving concepts in the pathogenesis of acne vulgaris. J Drugs Dermatol (2014) 0.78
The importance of photoprotection and moisturization in treating acne vulgaris. J Drugs Dermatol (2014) 0.78
Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis (2007) 0.78
A double-blind, placebo-controlled pilot study to estimate the efficacy and tolerability of a nonsteroidal cream for the treatment of cradle cap (seborrheic dermatitis). J Drugs Dermatol (2013) 0.78
Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin. J Clin Aesthet Dermatol (2011) 0.78
Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol (2011) 0.78
Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol (2016) 0.77
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. J Drugs Dermatol (2013) 0.77
Evolving perspectives on the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol (2015) 0.77
Overcoming the Barrier Treatment of Ichthyosis: A Combination-therapy Approach. J Clin Aesthet Dermatol (2010) 0.77
Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol (2012) 0.76
Treatment of facial photodamage using a novel retinol formulation. J Drugs Dermatol (2013) 0.76
Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach. J Drugs Dermatol (2014) 0.76
Re-evaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol (2014) 0.76
Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2014) 0.76
The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol (2013) 0.76
A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol (2014) 0.76
A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol (2010) 0.75
Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review. J Clin Aesthet Dermatol (2009) 0.75
Avoiding the legal "blemish": medicolegal pitfalls in dermatology. J Clin Aesthet Dermatol (2009) 0.75
Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. J Clin Aesthet Dermatol (2010) 0.75
A Comprehensive Review of Clocortolone Pivalate 0.1% Cream: Structural Development, Formulation Characteristics, and Studies Supporting Treatment of Corticosteroid-responsive Dermatoses. J Clin Aesthet Dermatol (2012) 0.75
Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment. J Drugs Dermatol (2016) 0.75
Primary carcinosarcoma of the ear: case report and review of the literature. J Clin Aesthet Dermatol (2009) 0.75
Atopic dermatitis and the stratum corneum: part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin. J Clin Aesthet Dermatol (2013) 0.75
Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol (2009) 0.75
Erythropoietic protoporphyria: a case report and literature review. J Clin Aesthet Dermatol (2010) 0.75
Efficacy and Tolerability of a Three-Step Acne System Containing a Solubilized Benzoyl Peroxide Lotion versus a Benzoyl Peroxide/Clindamycin Combination Product: An Investigator-Blind, Randomized, Parallel-Group Study. J Clin Aesthet Dermatol (2008) 0.75
What more can we learn about acne and rosacea? Just keep reading, questioning, and searching for clinical relevance beyond the limitations of clinical trials. J Drugs Dermatol (2013) 0.75
Randomized, controlled, evaluator-blinded studies conducted to compare the efficacy and tolerability of 3 over-the-counter acne regimens in subjects with mild or moderate acne. J Drugs Dermatol (2013) 0.75
The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2012) 0.75
The microsponge delivery system reduces facial oiliness and shine during acne therapy. J Drugs Dermatol (2013) 0.75
Spotlight on the Use of Nitric Oxide in Dermatology: What Is It? What Does It Do? Can It Become an Important Addition to the Therapeutic Armamentarium for Skin Disease? J Drugs Dermatol (2017) 0.75
Topical tazarotene in acne vulgaris: treatment approaches. Cutis (2004) 0.75
The effect of benzoyl peroxide 9.8% emollient foam on reduction of Propionibacterium acnes on the back using a short contact therapy approach. J Drugs Dermatol (2012) 0.75
Letter from the guest editor. J Drugs Dermatol (2012) 0.75
Practical aspects of topical corticosteroid selection. J Drugs Dermatol (2012) 0.75
Do we really need topical antibiotics in our new treatment paradigm of acne vulgaris? A novel question to consider based on an updated model of pathogenesis. J Drugs Dermatol (2013) 0.75
Put your best foot forward: advances in the management of tinea pedis. J Drugs Dermatol (2013) 0.75
Overstating Conclusions from Population-Based Data: Be Careful What You Wish For! J Drugs Dermatol (2016) 0.75
The changing face of challenges in the management of acne and rosacea. J Drugs Dermatol (2014) 0.75
The only topical retinoid without a generic alternative: tazarotene. J Drugs Dermatol (2013) 0.75
Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. J Drugs Dermatol (2014) 0.75
Management of Acne & Rosacea: Working Toward the Same Goals…Facing New Challenges. J Drugs Dermatol (2015) 0.75
Over-the-counter product role in the daily management of atopic dermatitis: achieving success with advanced technology. J Drugs Dermatol (2013) 0.75
Not all topical corticosteroids are created equal! Optimizing therapeutic outcomes through better understanding of vehicle formulations, compound selection,and methods of application. J Drugs Dermatol (2012) 0.75